Novel Approaches to Target MECOM/EVI1 in AML
About this study
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
- Condition
- AML, Adult
- Tested
- Biological characterization of AML with MECOM or atypical 3q26 rearrangements
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Study condition: AML, Adult
- AML with MECOM or atypical 3q26 rearrangements.
- Age ≥18.
- Signed written informed consent according to ICH/EU/GCP and national local laws.
Where
1 site, 1 recruiting
Ematologia
Piacenza, Italy
Contact
-
Paola Fazi
0670390528 p.fazi@gimema.it
-
Enrico Crea
0670390514 e.crea@gimema.it
Potential match only. Final eligibility is determined by the study team.